Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.

Pathology, research and practice - 1 Aug 2022

Marchese Paola Valeria, Mollica Veronica, De Biase Dario, Giunchi Francesca, Tassinari Elisa, Marchetti Andrea, Rosellini Matteo, Nuvola Giacomo, Maloberti Thais, Fiorentino Michelangelo, Massari Francesco

Abstract excerpt

BACKGROUND: The therapeutic scenario of urothelial carcinoma is constantly expanding with the widening of the knowledge on molecular characteristics, thus claiming for the need of prognostic and predictive factors to guide treatment strategy. TERT promoter mutation is one of the most frequent genomic alterations in urothelial carcinoma and could present several implications, from diagnostic to prognostic or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 35751929
DOI: 10.1016/j.prp.2022.153983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.PMID 35751929Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.Semantic proximity Read ↗

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaSemantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.Semantic proximity Read ↗

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancerSemantic proximity Read ↗

High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.Semantic proximity Read ↗

Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.Semantic proximity Read ↗

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.Semantic proximity Read ↗

Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges.Semantic proximity Read ↗

TERT Promoter Mutations in Penile Squamous Cell Carcinoma: High Frequency in Non-HPV-related Type and Association With Favorable Clinicopathologic FeaturesSemantic proximity Read ↗

Emerging targets in upper tract urothelial carcinomas: the TERT gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.